Schonfeld Strategic Advisors LLC C4 Therapeutics, Inc. Transaction History

Schonfeld Strategic Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.18 - $6.03 $120,807 - $617,345	102,379 New	102,379 $578,000
Q3 2022 Nov 14, 2022	BUY	$8.03 - $12.77 $191,603 - $304,704	23,861 New	23,861 $210,000
Q2 2022 Aug 15, 2022	SELL	$5.06 - $26.46 $453,689 - $2.37 Million	-89,662 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$19.99 - $33.23 $890,554 - $1.48 Million	44,550 Added 98.75%	89,662 $2.18 Million
Q4 2021 Feb 14, 2022	SELL	$29.39 - $46.86 $503,773 - $803,227	-17,141 Reduced 27.53%	45,112 $1.45 Million
Q3 2021 Nov 16, 2021	BUY	$35.91 - $50.5 $2.24 Million - $3.14 Million	62,253 New	62,253 $2.78 Million

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $208M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.